Renal Issues with Alectinib
No dose adjustment is required for alectinib in patients with mild to moderate renal impairment (creatinine clearance 30-89 mL/min), but the drug has not been studied in severe renal impairment (CrCl <30 mL/min) or end-stage renal disease 1.
Key Renal Considerations
Dose Adjustments Based on Renal Function
- Mild to moderate renal impairment (CrCl 30-89 mL/min): No dose adjustment needed 1
- Severe renal impairment (CrCl <30 mL/min): Not studied; safety unknown 1
- End-stage renal disease/dialysis: Not studied in clinical trials 1
The FDA label explicitly states that age, body weight, mild hepatic impairment, mild to moderate renal impairment, race, and sex had no clinically meaningful effect on alectinib and M4 (active metabolite) exposure 1.
Acute Kidney Injury Risk
Alectinib can cause acute kidney injury (AKI), though this is rare (reported in <1% of cases). Several case reports document severe renal toxicity:
- Anuric AKI: A 71-year-old diabetic patient developed anuria and creatinine elevation from 1.0 to 3.64 mg/dL after 2 months of alectinib 600 mg twice daily, requiring hemodialysis 2
- Mixed acute interstitial nephritis (AIN) and acute tubular necrosis (ATN): A 68-year-old patient developed AKI 27 days after starting alectinib, confirmed by renal biopsy showing both AIN and ATN patterns 3
- Progressive glomerulonephritis: Developed 1 year after alectinib initiation, with unique tubular and glomerular lesions on biopsy 4
Monitoring Recommendations
Monitor renal function closely, especially in patients with:
- Pre-existing renal impairment
- Diabetes mellitus
- Concurrent nephrotoxic medications
- Baseline creatinine clearance near threshold values
The case reports demonstrate that AKI can occur at any time during treatment—from 27 days to 1 year after initiation 3, 4.
Management of Renal Toxicity
If AKI develops:
- Immediately discontinue alectinib 2, 3, 4
- Provide supportive care including hydration and discontinuation of other nephrotoxic agents
- Consider corticosteroids if AIN is suspected (showed partial reversal in one case) 4
- Hemodialysis may be required for severe cases 2, 3
- Do not rechallenge with alectinib if severe AKI occurred—one case showed recurrent dysfunction upon re-administration 4
Alternative ALK Inhibitors
Switch to brigatinib or lorlatinib if alectinib causes renal toxicity:
- Brigatinib was well-tolerated with stable renal function at 4-month follow-up in one patient who developed anuric AKI on alectinib 2
- Lorlatinib maintained stable renal function for 10 months in another patient with alectinib-induced AKI 3
Special Population: Hemodialysis Patients
Limited data suggest alectinib may be feasible in hemodialysis patients at reduced doses. One case report showed:
- 300 mg twice daily achieved therapeutic plasma concentrations (Cmax 638 ng/mL for alectinib, 82 ng/mL for M4) similar to patients with normal renal function 5
- Hemodialysis did not significantly alter drug levels (trough concentrations identical pre- and post-dialysis) 5
- Patient achieved partial remission maintained at 12 months 5
This suggests alectinib is not significantly removed by hemodialysis due to >99% protein binding 1, though this represents only a single case report.
Dose Reduction Strategy
For patients with borderline renal function or those who develop mild renal impairment, consider starting at 300 mg twice daily (the approved Japanese dose) rather than the standard 600 mg twice daily, particularly in patients with:
- Body weight ≤60 kg
- No baseline brain metastases
- Borderline renal function 6
One patient successfully managed alectinib-induced renal dysfunction with dose reduction to 140 mg twice daily using a 2-weeks-on/2-weeks-off schedule, achieving partial response for 16 months 7.
Pharmacokinetic Considerations
Alectinib undergoes minimal renal excretion (<0.5% unchanged in urine), with 98% excreted in feces 1. However, the active metabolite M4 accumulation in severe renal impairment remains unstudied and could theoretically contribute to toxicity.